ConductScience.org, home

Comparison · NCT04819438-deaths

Riluzole Orodispersible Film (Test) vs Rilutek® (Reference): deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Riluzole Orodispersible Film (Test) vs Rilutek® (Reference): deaths from any cause. Trial comparisons, record NCT04819438-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04819438-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0688wilson
Risk in group 2000.0676wilson
Risk difference, group 1 minus group 20-0.06760.0688newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Riluzole Orodispersible Film (Test)
The subjects were treated with one orodispersible film containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence~Riluzole 50 mg Oral Film: Before each administration, the subjects drank 20 mL of still mineral water in order to wet their mouth. Afterwards, using gloves, the investigator or deputy took the orodispersible film (32.0x22.0 mm) out of the provided pouch and placed the product directly on the top surface (dorsal aspect) of the subjects' tongue.
052EG000
Group 2Rilutek® (Reference)
The subjects were treated with one film-coated table containing 50 mg of riluzole in two out of the four study periods according to the randomisation sequence~Rilutek 50Mg Tablet: One film-coated tablet was swallowed (without chewing) with 150 mL of still mineral water.
053EG001

Harm

What it counts
Total, all-cause mortality
Time frame
36 days

Source ClinicalTrials.gov

Trial

Title
Riluzole Orodispersible Film Replicate Bioavailability
NCT number
NCT04819438
Phases
PHASE1
Conditions
Healthy Participants
Interventions
Riluzole 50 mg orodispersible film, Rilutek® 50 mg riluzole tablets
Lead sponsor
Cross Research S.A.
Results first posted
2025-05-02

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04819438-deaths